MRA Treatment Ups Hyperkalemia Risk, but Not Death in CKD
Mineralocorticoid receptor antagonist treatment is often not recommended in patients with advanced kidney disease due to perceived risk of hyperkalemia and death, investigators noted.
Diagnosis & Disease Information
Sparsentan Gets Priority Review for IgA Nephropathy
The FDA has accepted for Priority Review the New Drug Application for sparsentan for the treatment of IgA nephropathy.
Enrollment Paused in Trials Evaluating BCX9930 for Complement-Mediated Diseases
BCX9930 is an investigational oral Factor D inhibitor.
First Generic Version of Apokyn Drug Cartridges Gets FDA Approval
The approval is only for the drug cartridges, which are compatible for use with the Apokyn Pen, the brand name pen injector.
Terlipressin Decision Delayed Due to Manufacturing Facility Change
In the CRL, the FDA stated that a satisfactory inspection is required before the NDA can be approved.
SGLT2 Inhibitors Underprescribed for Chronic Kidney Disease
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Tarpeyo Now Available to Reduce Proteinuria in Primary IgA Nephropathy
To help patients gain access to treatment, Calliditas Therapeutics has launched a patient support program called Tarpeyo Touchpoints.
Tarpeyo Approved to Reduce Proteinuria in Primary IgA Nephropathy
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tarpeyo in 299 adults with primary IgAN.
ACR: Risk Factors ID’d for Hydroxychloroquine-Related Retinopathy
Independent risk factors for HCQ retinopathy include higher doses, longer duration of use, chronic kidney disease, and Asian race
ASN: Steroids Best Placebo in High-Risk IgA Nephropathy
But dose reduced because of increased incidence of serious adverse events with full-dose methylprednisolone
